Trials / Not Yet Recruiting
Not Yet RecruitingNCT06974175
Effect of Graminex on Infertility Related to Male Accessory Glands Inflammation
Effect of Graminex on Infertility Related to Male Accessory Glands Inflammation. Pilot Study
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Academic / Other
- Sex
- Male
- Age
- 20 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
Male Accessory Glands Inflammations (MAGI) include inflammatory diseases involving seminal vescicles and the prostate. Patients suffering from them present an impaired fertility because of seminal duct obstruction and alterations of the rheologic and functional parameters of semen, induced by direct microbiological action as well as inflammatory and oxidative damage. Inflammation in seminal plasma can be detected and measured by dosing of inflammatory molecules such as SuPAR and ST2. Treatment of MAGIs include specific antibiotic therapy in addition to use of anti-inflammatory nutraceutics. Deprox HP is a nutraceutic containing GraminexTM, a compound made of pollen extracts of rye, mais and timothy. To investigate its efficacy, we evalued seminal parameters, inflammatory and oxidative molecules in seminal plasma and clinical and ultrasonographic features of male accessory glands before and after 3 months of treatment in 20 patients taking Deprox HP and 20 patients undergoing treatment with palmitoilethanolammide, bromelin and horse chestnut extract.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Deprox_HP | Use of nutraceutic based on a compound of pollen extracts from pollen, mais and timothy |
| OTHER | Peacist | Use of a nutraceutic based on palmitoilethanolamide + Bromelin + Horse Chestunt extract |
Timeline
- Start date
- 2025-09-01
- Primary completion
- 2026-03-30
- Completion
- 2026-05-01
- First posted
- 2025-05-15
- Last updated
- 2025-08-14
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT06974175. Inclusion in this directory is not an endorsement.